Supercharged immune cells take aim at multiple cancer types in early trial
NCT ID NCT03132922
First seen May 13, 2026 · Last updated May 16, 2026 · Updated 1 time
Summary
This early-phase study tests a personalized cell therapy for people with certain advanced cancers (bladder, melanoma, head/neck, ovarian, lung, esophageal, stomach, sarcoma) that carry a protein called MAGE-A4. Patients' own immune cells are genetically modified to recognize and attack tumors. The main goals are to check safety and see if the treatment shrinks tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Duke University Medical Center, Duke Cancer Institute
Durham, North Carolina, 27710, United States
-
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19111, United States
-
M.D. Anderson Cancer Center
Houston, Texas, 77030, United States
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
Ohio State University Wexner Medical Center
Columbus, Ohio, 43210, United States
-
Princess Margaret Cancer Centre
Toronto, Ontario, M5G1X6, Canada
-
Roswell Park Cancer Institute
Buffalo, New York, 14263, United States
-
Tennessee Oncology - Sarah Cannon Research Institute
Nashville, Tennessee, 37203, United States
-
University of Miami
Miami, Florida, 33136, United States
-
Washington University
St Louis, Missouri, 63112, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.